Sci Technology develops bio pharmaceutical drugs by combining proteins with special formulation technologies for the treatment of various diseases
Since Sci Technology GmbH was founded more than 15 years ago, the company develops innovative bio pharmaceuticals to fight disorders related to ageing. Cutting-edge biological science and applied research is used to develop novel therapies for patients suffering from age related degenerative and inflammatory disorders. The pipeline covers promising per-clinical and clinical development programs in osteoarthritis, inflammatory joint disease, cartilage injury and severe vaginal inflammation. License deals have been concluded with leading pharma companies for development programs in different indications.
Sci Technology is now seeking partnership with a major pharmaceutical company to exploit the full potential of its disease modifying arthritis program and to progress development as quickly as possible from bench to patients.
Scil Technology, located in Martinsried/Munich, is highly experienced in the development of biopharmaceutical drugs with special know-how in demanding formulations. Whilst the portfolio already covers a variety of indications for development programs from the orthopedic field and dental surgery to rheumatoid arthritis, further indications are being added to our portfolio. In addition, the indications can be administered in several ways including medical devices, pharmaceutical drugs and finally regenerative medical products. Indications with high unmet medical needs are addressed, with the prerequisite to find the best formulation for maximum efficacy.
Several projects have passed clinical proof of concept and a further two development programs have successfully passed clinical phase II at Sci Technology. License deals have been concluded with leading pharma companies for development programs for different indications.
Scil Technology distinguishes through its unique expertise in drug development covering the whole value chain from target validation up to clinical phase III.
As part of its business unit Biologic Development, Sci Technology GmbH develops not only successfully innovative bio pharmaceutical drug candidates based on proprietary proteins, but also has the expertise to design tailor-made formulations for well known proteins to extend their field of application. Thus Sci Technology made it their business to create innovative disease modifying bio pharmaceuticals from early research up to phase III.